Parmax Pharma Ltd
Parmax Pharma Ltd Live Price Chart
Performance
| Previous Close | ₹ 135.05 |
| High | ₹ 136.4 |
| Volume | |
| 52W Range | ₹ 22.6 - ₹ 135.05 |
| Open | ₹ 136.4 |
| Low | ₹ 136.4 |
| Market Cap | ₹ 91.11 Cr |
Parmax Pharma Ltd Technicals
| 20 Day | ₹ 119.892 |
| 50 Day | ₹ 101.257 |
| 100 Day | ₹ 80.709 |
| 200 Day | ₹ 62.611 |
| 20 Day | ₹ 124.204 |
| 50 Day | ₹ 100.979 |
| 100 Day | ₹ 75.039 |
| 200 Day | ₹ 52.159 |
Parmax Pharma Ltd Fundamentals
| ROCE | -85.761 |
| P/E Ratio | -77.610 |
| P/B Ratio | 20.220 |
| Industry P/E | 20.220 |
| Debt to Equity | 51.202 |
| ROE | 67.652 |
| EPS | -1.740 |
| Dividend Yield | 0.000 |
| Book Value | 6.679 |
| Face Value | 10.000 |
Parmax Pharma Ltd Financials
| Particulars | Y202603 | Y202503 | Y202403 | Y202303 | Y202203 |
|---|---|---|---|---|---|
| Total Revenue | 12.1583991 | 28.2435355 | 11.1011504 | 15.464066258 | 18.3148362 |
| Total Expenses | 18.0041295 | 29.5666773 | 16.7570246 | 15.417943165 | 18.0115662 |
| Profit After Tax | -4.1590818 | -2.0940101 | -5.7505216 | -0.104068307 | 0.1415133 |
Parmax Pharma Ltd Shareholding Pattern
| Promoter Holdings | 64.659 % |
| FIIs | 0.000 % |
| DIIs | 0.000 % |
| MutualFund | 0.000 % |
| Retail | 34.740 % |
| Others - | 0.602 % |
About Parmax Pharma Ltd
Incorporated in November, 1994, Parmax Pharma Limited (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara. The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations. The Company has manufacturing facilities approved by Indian regulatory bodies such as CDSCO, State FDA, and operates under GMP-compliant systems. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc. The Company then discontinued their business activities for few years due to various reasons. Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA. Antibiotic project was fully implemented from 31st May'97. The core segments of the Company comprise of Anti-Infectives, Analgesics & anti-inflammatory; Cardiovascular APIs and General oral formulations (tablets, capsules). Apart from this, the Company works a stable growth in API volumes due to consistent domestic demand. It has marginal increase in pricing due to higher input costs passed on. It has improved the plant utilization especially in Q3 and Q4. It works minor exports to neighboring countries like B ...
Similar Stocks
| Ambalal Sarabhai Enterprises Ltd Pharmaceuticals | ₹ 39.05 -1.4 (-3.46%) |
| Amrutanjan Health Care Ltd Pharmaceuticals | ₹ 496.30 +2.65 (+0.54%) |
| Astrazeneca Pharma India Ltd Pharmaceuticals | ₹ 6,710.55 -40.85 (-0.61%) |
| Bliss GVS Pharma Ltd Pharmaceuticals | ₹ 662.00 -18.4 (-2.7%) |
| Abbott India Ltd Pharmaceuticals | ₹ 27,112.50 -160.8 (-0.59%) |
| Cipla Ltd Pharmaceuticals | ₹ 1,391.40 +19.95 (+1.45%) |
FAQs on Parmax Pharma Ltd
1. Can I buy Parmax Pharma Ltd from PL Capital? ›
2. Does Parmax Pharma Ltd pay dividends? ›
3. What is the current share price of Parmax Pharma Ltd ? ›
4. What is the 52-week high and low of Parmax Pharma Ltd ? ›
5. What is the market capitalisation of Parmax Pharma Ltd? ›
6. What is the current P/E ratio of Parmax Pharma Ltd? ›
7. What is the current P/B ratio of Parmax Pharma Ltd? ›
8. What is the shareholding pattern of Parmax Pharma Ltd? ›
9. What is the 1-year return of Parmax Pharma Ltd? ›
Start SIP in Parmax Pharma Ltd
Invest systematically in stocks with the
PL Capital app
Are you a new user? Open your account
